[Skip to Content]
[Skip to Content Landing]
March 1982

Calcium Channel Blockers for Cardiovascular Disorders

Author Affiliations

From the Cardiovascular Section, Veterans Administration Medical Center, Long Beach, Calif; and the Department of Medicine, University of California, Irvine.

Arch Intern Med. 1982;142(3):452-455. doi:10.1001/archinte.1982.00340160036009

The calcium channel blocking agents are an exciting, entirely new class of drugs that will have widespread application in this country during the next several years. Actually, clinical experience with these drugs around the globe has already been extensive. However, many of the older studies performed with these agents, some of which had less-than-optimal controls, have for many years not met the vigorous standards of our regulatory agencies. Most would agree that this delay has been appropriate since, even during the writing of this article, critical clarification of these drugs continues. Some internationally performed studies have met with the rigorous investigational criteria expected by our regulatory agencies, but the bulk of studies that will eventually permit some of these drugs to reach our US market is currently being performed or has just recently been published. Until such time as a comprehensive evaluation is possible, initial approval will be limited to

Ellradt G, Chew CYC, Singh BH:  Therapeutic implications of slowchannel blockade in cardiocirculatory disorders.  Circulation 1980;62:669-677.Crossref
Antman EM, Stone PH, Muller JE, et al:  Calcium channel blocking agents in the treatment of cardiovascular disorders: I. Basic and clinical electrophysiologic effects.  Ann Intern Med 1980;93:875-885.Crossref
Stone PH, Antman EM, Muller JE, et al:  Calcium channel blocking agents in the treatment of cardiovascular disorders: II. Hemodynamic effects and clinical applications.  Ann Intern Med 1980;93:886-904.Crossref
Henry P:  Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem.  Am J Cardiol 1980;46:1047-1058.Crossref
Aronow WS, Landa D, Plasencia G, et al:  Verapamil in atrial fibrillation and atrial flutter.  Clin Pharmacol Ther 1979;26:578-583.
Aronow WS, Plasencia G, Wong R, et al:  Effect of verapamil versus placebo on PAT and MAT (paroxysmal atrial tachycardia and multifocal atrial tachycardia).  Curr Ther Res 1980;27:823-829.
Kimura E, Kishida H:  Treatment of variant angina with drugs: A survey of 11 cardiology institutes in Japan.  Circulation 1981;63:844-848.Crossref
Johnson SM, Mauritson DR, Willerson JT, et al:  A controlled trial of verapamil for Prinzmetal's variant angina.  N Engl J Med 1981;304:862-866.Crossref
Ferlinz J, Turbow ME:  Antianginal and myocardial metabolic properties of verapamil in coronary artery disease.  Am J Cardiol 1980;46:1019-1026.Crossref
Ferlinz J, Easthope JL, Aronow WS:  Effects of verapamil on myocardial performance in coronary disease.  Circulation 1979;59:313-319.Crossref
Chew CYC, Hecht HS, Collett JT, et al:  Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease.  Am J Cardiol 1981;47:917-922.Crossref
Karlsberg RP, Aronow WS:  Reduction of myocardial infarct size: Approach for the 1980s.  Arch Intern Med 1980;140:616-619.Crossref
Karlsberg RP, Henry PD, Ahmed SA, et al:  Lack of protection of ischemic myocardium by verapamil in conscious dogs.  Eur J Pharmacol 1977;42:339-346.Crossref
Henry PD, Shuchleib R, Borda LJ, et al:  Effects of nifedipine on myocardial perfusion and ischemic injury in dogs.  Circ Res 1978;43:372-380.Crossref
Clark RE, Christlieb IY, Henry PD, et al:  Nifedipine: A myocardial protective agent.  Am J Cardiol 1979;44:827-833.